Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia

• Status: Terminated
• Trial end date: 2018-08-15
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of this study is to evaluate the effect of the addition of idelalisib to ofatumumab on progression-free survival (PFS) in participants with previously treated chronic lymphocytic leukemia (CLL).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Gilead Sciences
• Treatments: Antibodies, Monoclonal; Idelalisib; Ofatumumab

Criteria

Key Inclusion Criteria:

• Adults with previously treated recurrent CLL who have measurable lymphadenopathy

• Require therapy for CLL

• Have experienced CLL progression < 24 months since the completion of the last prior therapy

• Have disease that is not refractory to ofatumumab

Note: Other protocol defined Inclusion/Exclusion criteria may apply.